Table of Contents Author Guidelines Submit a Manuscript
International Journal of Hepatology
Volume 2011 (2011), Article ID 136816, 12 pages
http://dx.doi.org/10.4061/2011/136816
Research Article

NCX 1000 Alone or in Combination with Vitamin E Reverses Experimental Nonalcoholic Steatohepatitis in the Rat Similarly to UDCA

1Natural Health Products and Metabolic Diseases Laboratory, Department of Pharmacology Université de Montréal and Montreal Diabetes Research Center, Montreal, QC, Canada H3C 3J7
2Institute of Nutraceutical and Functional Foods, Laval University, Sillery, QC, Canada GIV 0A6
3Department of Pharmacology, Université de Montréal, Montreal, QC, Canada H3C 3J7
4R & D Axcan Pharma Inc, Mont-St-Hilaire, QC, Canada J3H 6C4

Received 17 February 2011; Accepted 20 June 2011

Academic Editor: Takuji Torimura

Copyright © 2011 Yara Haddad et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Ludwig, T. R. Viggiano, D. B. McGill, and B. J. Ott, “Nonalcoholic steatohepatitis: mayo Clinic experiences with a hitherto unnamed disease,” Mayo Clinic Proceedings, vol. 55, no. 7, pp. 434–438, 1980. View at Google Scholar · View at Scopus
  2. S. Bellentani and M. Marino, “Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD),” Annals of Hepatology, vol. 8, 1, pp. S4–S8, 2009. View at Google Scholar · View at Scopus
  3. G. Marchesini, E. Bugianesi, G. Forlani et al., “Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome,” Hepatology, vol. 37, no. 4, pp. 917–923, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. G. Pagano, G. Pacini, G. Musso et al., “Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association,” Hepatology, vol. 35, no. 2, pp. 367–372, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Capeau, “Insulin resistance and steatosis in humans,” Diabetes & Metabolism, vol. 34, no. 6, part 2, pp. 649–657, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. H. Malhi and G. J. Gores, “Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease,” Seminars in Liver Disease, vol. 28, no. 4, pp. 360–369, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. E. M. Brunt and D. G. Tiniakos, “Pathological features of NASH,” Frontiers in Bioscience, vol. 10, pp. 1475–1484, 2005. View at Google Scholar · View at Scopus
  8. A. Nonomura, Y. Enomoto, M. Takeda et al., “Clinical and pathological features of non-alcoholic steatohepatitis,” Hepatology Research, vol. 33, no. 2, pp. 116–121, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. H. Malhi and G. J. Gores, “Cellular and molecular mechanisms of liver injury,” Gastroenterology, vol. 134, no. 6, pp. 1641–1654, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. C. D. Byrne, R. Olufad, K. D. Bruce, F. R. Cagampang, and M. H. Ahmed, “Metabolic disturbances in non-alcoholic fatty liver disease,” Clinical Science, vol. 116, no. 7, pp. 539–564, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. B. A. Neuschwander-Tetri and S. H. Caldwell, “Nonalcoholic steatohepatitis: summary of an AASLD single topic conference,” Hepatology, vol. 37, no. 5, pp. 1202–1219, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. P. Ljubuncic, Z. Tanne, and A. Bomzon, “. Ursodeoxycholic acid suppresses extent of lipid peroxidation in diseased liver in experimental cholestatic liver disease,” Digestive Diseases and Sciences, vol. 45, no. 10, pp. 1921–1928, 2000. View at Publisher · View at Google Scholar · View at Scopus
  13. V. U. Buko, O. YA. Lukivskaya, L. B. Zavodnik, V. V. Sadovnichy, N. E. Petushok, and H. D. Tauschel, “Antioxidative effect of ursodeoxycholic acid in the liver of rats with oxidative stress caused by gamma-irradiation,” Ukrainskii Biokhimicheskii Zhurnal, vol. 74, no. 1, pp. 88–92, 2002. View at Google Scholar · View at Scopus
  14. C. Y. Chang, C. K. Argo, A. M. S. Al-Osaimi, and S. H. Caldwell, “Therapy of NAFLD: antioxidants and cytoprotective agents,” Journal of Clinical Gastroenterology, vol. 40, 1, pp. S51–S60, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. P. Angulo, “Use of ursodeoxycholic acid in patients with liver disease,” Current Gastroenterology Reports, vol. 4, no. 1, pp. 37–44, 2002. View at Google Scholar · View at Scopus
  16. D. Festi, M. Montagnani, F. Azzaroli et al., “Clinical efficacy and effectiveness of ursodeoxycholic acid in cholestatic liver diseases,” Current Clinical Pharmacology, vol. 2, no. 2, pp. 155–177, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Trauner, P. Fickert, E. Halilbasic, and T. Moustafa, “Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases,” Wiener Medizinische Wochenschrift, vol. 158, no. 19-20, pp. 542–548, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. D. Kumar and R. K. Tandon, “Use of ursodeoxycholic acid in liver diseases,” Journal of Gastroenterology and Hepatology, vol. 16, no. 1, pp. 3–14, 2001. View at Publisher · View at Google Scholar · View at Scopus
  19. M. L. Balmer, K. Siegrist, A. Zimmermann, and J. F. Dufour, “Effects of ursodeoxycholic acid in combination with vitamin E on adipokines and apoptosis in patients with nonalcoholic steatohepatitis,” Liver International, vol. 29, no. 8, pp. 1184–1188, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. J. Laurin, K. D. Lindor, J. S. Crippin et al., “Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study,” Hepatology, vol. 23, no. 6, pp. 1464–1467, 1996. View at Google Scholar · View at Scopus
  21. E. F. Georgescu and M. Georgescu, “Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study,” Journal of Gastrointestinal and Liver Diseases, vol. 16, no. 1, pp. 39–46, 2007. View at Google Scholar · View at Scopus
  22. J. Dufour, C. M. Oneta, J. J. Gonvers et al., “Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis,” Clinical Gastroenterology and Hepatology, vol. 4, no. 12, pp. 1537–1543, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. J. G. Fan, L. Zhong, LI. Y. Tia, Z. J. Xu, M. S. Li, and G. L. Wang, “Effects of ursodeoxycholic acid and/or low-calorie diet on steatohepatitis in rats with obesity and hyperlipidemia,” World Journal of Gastroenterology, vol. 11, no. 15, pp. 2346–2350, 2005. View at Google Scholar · View at Scopus
  24. K. D. Lindor, K. V. Kowdley, E. J. Heathcote et al., “Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial,” Hepatology, vol. 39, no. 3, pp. 770–778, 2004. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Fiorucci, E. Antonelli, V. Brancaleone et al., “NCX-1000, a nitric oxide-releasing derivative of ursodeoxycholic acid, ameliorates portal hypertension and lowers norepinephrine-induced intrahepatic resistance in the isolated and perfused rat liver,” Journal of Hepatology, vol. 39, no. 6, pp. 932–939, 2003. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Fiorucci, E. Antonelli, E. Distrutti et al., “Liver delivery of NO by NCX-1000 protects against acute liver failure and mitochondrial dysfunction induced by APAP in mice,” British Journal of Pharmacology, vol. 143, no. 1, pp. 33–42, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Fiorucci, E. Antonelli, and A. Morelli, “Nitric oxide and portal hypertension: a nitric oxide-releasing derivative of ursodeoxycholic acid that selectively releases nitric oxide in the liver,” Digestive and Liver Disease, vol. 35, pp. S61–69, 2003. View at Google Scholar · View at Scopus
  28. S. Fiorucci, E. Antonelli, O. Morelli et al., “NCX-1000, a NO-releasing derivative of ursodeoxycholic acid, selectively delivers NO to the liver and protects against development of portal hypertension,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 15, pp. 8897–8902, 2001. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Fiorucci, A. Mencarelli, B. Palazzetti, P. Del Soldato, A. Morelli, and L. J. Ignarro, “An NO derivative of ursodeoxycholic acid protects against Fas-mediated liver injury by inhibiting caspase activity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 5, pp. 2652–2657, 2001. View at Publisher · View at Google Scholar · View at Scopus
  30. M. R. Loureiro-Silva, G. W. Cadelina, Y. Iwakiri, and R. J. Groszmann, “A liver-specific nitric oxide donor improves the intra-hepatic vascular response to both portal blood flow increase and methoxamine in cirrhotic rats,” Journal of Hepatology, vol. 39, no. 6, pp. 940–946, 2003. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Ouazzani-Chahdi, A. Elimadi, A. Chabli, J. Spénard, P. Colin, and P. S. Haddad, “Combining ursodeoxycholic acid or its NO-releasing derivative NCX-1000 with lipophilic antioxidants better protects mouse hepatocytes against amiodarone toxicity,” Canadian Journal of Physiology and Pharmacology, vol. 85, no. 2, pp. 233–242, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. C. S. Lieber, M. A. Leo, KI. M. Mak et al., “Model of nonalcoholic steatohepatitis,” American Journal of Clinical Nutrition, vol. 79, no. 3, pp. 502–509, 2004. View at Google Scholar · View at Scopus
  33. P. M. Huet, M. R. Nagaoka, G. Desbiens et al., “Sinusoidal endothelial cell and hepatocyte death following cold ischemia-warm reperfusion of the rat liver,” Hepatology, vol. 39, no. 4, pp. 1110–1119, 2004. View at Publisher · View at Google Scholar · View at Scopus
  34. D. E. Kleiner, E. M. Brunt, M. Van Natta et al., “Design and validation of a histological scoring system for nonalcoholic fatty liver disease,” Hepatology, vol. 41, no. 6, pp. 1313–1321, 2005. View at Publisher · View at Google Scholar · View at Scopus
  35. E. M. Brunt, C. G. Janney, A. M. Di Bisceglie, B. A. Neuschwander-Tetri, and B. R. Bacon, “Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions,” American Journal of Gastroenterology, vol. 94, no. 9, pp. 2467–2474, 1999. View at Publisher · View at Google Scholar · View at Scopus
  36. L. M. P.S. Hettihawa, S. S. Jayasinhe, S. W. Gunasekara, and T. P. Weerarathna, “Comaparison of insulin resistance by indirect methods—HOMA, QUICKI, and MCAuley—with fasting insulin in patients with type 2 diabetes in Galle, Sri Lanka: a pilot study,” Online Journal of Health and Allied Sciences, vol. 5, no. 1, p. 2, 2006. View at Google Scholar
  37. D. L. H. Johnson and H. Lardy, “Isolation of liver and kidney mitochondria,” in Methods in Enzymology, R. W. Estabrook and M. E. Pullman, Eds., vol. 10, pp. 94–96, Academic Press, New York, NY, USA, 1967. View at Google Scholar
  38. O. H. Lowry, N. J. Rosebrough, A. L. Farr, and R. J. Randall, “Protein measurement with the Folin phenol reagent,” The Journal of Biological Chemistry, vol. 193, no. 1, pp. 265–275, 1951. View at Google Scholar · View at Scopus
  39. H. Ligeret, A. Brault, D. Vallerand, Y. Haddad, and P. S. Haddad, “Antioxidant and mitochondrial protective effects of silibinin in cold preservation-warm reperfusion liver injury,” Journal of Ethnopharmacology, vol. 115, no. 3, pp. 507–514, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. P. J. Oliveira, A. P. Rolo, C. M. Palmeira, and A. J. M. Moreno, “Carvedilol reduces mitochondrial damage induced by hypoxanthine/xanthine oxidase: relevance to hypoxia/reoxygenation injury,” Cardiovascular Toxicology, vol. 1, no. 3, pp. 205–213, 2001. View at Publisher · View at Google Scholar · View at Scopus
  41. G. C. Farrell and C. Z. Larter, “Nonalcoholic fatty liver disease: from steatosis to cirrhosis,” Hepatology, vol. 43, no. 2, pp. S99–S112, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. S. Caldwell and M. Lazo, “Is exercise an effective treatment for NASH? Knowns and unknowns,” Annals of Hepatology, vol. 8, supplement 1, pp. S60–S66, 2009. View at Google Scholar · View at Scopus
  43. R. Ali and K. Cusi, “New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD),” Annals of Medicine, vol. 41, no. 4, pp. 265–278, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. B. P. Lam and Z. M. Younossi, “Treatment regimens for non-alcoholic fatty liver disease,” Annals of Hepatology, vol. 8, supplement 1, pp. S51–S59, 2009. View at Google Scholar · View at Scopus
  45. C. D. Fisher, A. J. Lickteig, L. M. Augustine et al., “Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of non-alcoholic fatty liver disease,” Drug Metabolism and Disposition, vol. 37, no. 10, pp. 2087–2094, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. J. M. Hui, A. Hodge, G. C. Farrell, J. G. Kench, A. Kriketos, and J. George, “Beyond insulin resistance in NASH: TNF-α or adiponectin?” Hepatology, vol. 40, no. 1, pp. 46–54, 2004. View at Publisher · View at Google Scholar · View at Scopus
  47. C. Z. Larter and G. C. Farrell, “Insulin resistance, adiponectin, cytokines in NASH: which is the best target to treat?” Journal of Hepatology, vol. 44, no. 2, pp. 253–261, 2006. View at Publisher · View at Google Scholar · View at Scopus
  48. T. Hasegawa, M. Yoneda, K. Nakamura, I. Makino, and A. Terano, “Plasma transforming growth factor-β1 level and efficacy of α-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study,” Alimentary Pharmacology and Therapeutics, vol. 15, no. 10, pp. 1667–1672, 2001. View at Publisher · View at Google Scholar · View at Scopus
  49. J. E. Lavine, “Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study,” Journal of Pediatrics, vol. 136, no. 6, pp. 734–738, 2000. View at Google Scholar · View at Scopus